Literature DB >> 1516607

Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

P A Soons1, T Ankermann, D D Breimer, W Kirch.   

Abstract

The pharmacokinetics of the enantiomers of nitrendipine has been studied in seven elderly patients with chronic renal failure (CRF) and in six control subjects (mean creatinine clearance 30 and 97 ml.min-1 respectively). Racemic nitrendipine 20 mg was given once daily for seven days and the pharmacokinetics of the enantiomers over the last dosage interval were determined using a stereospecific assay. In both groups nitrendipine exhibited stereoselective pharmacokinetics (AUC, Cmax), but the half-lives of the enantiomers did not differ in individual subjects. As an index of stereoselectivity, the mean S/R ratio of AUCs in control subjects (2.07) was not significantly different from the ratio in patients with CRF (2.68). The mean AUCs of (S)- and (R)-nitrendipine during the last dosage interval were increased in CRF by 132% and 85%, respectively. The observed doubling of the half-lives and the increases in Cmax did not reach significance because of the large variability in each group. Thus, the pharmacokinetics of oral nitrendipine is altered in CRF, but there was no change in the stereoselectivity of its pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516607     DOI: 10.1007/bf00280129

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men.

Authors:  B Bengtsson-Hasselgren; O Rönn; L O Blychert; B Edgar; S Raner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.

Authors:  T Ankermann; U Osterkamp; S R Santos; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Inter- and intra-subject variability of nitrendipine and the effects of food.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Gas chromatographic analysis of nitrendipine and its pyridine metabolite in human plasma.

Authors:  P A Soons; D D Breimer
Journal:  J Chromatogr       Date:  1988-07-15

6.  Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma.

Authors:  P A Soons; M C Roosemalen; D D Breimer
Journal:  J Chromatogr       Date:  1990-06-29

7.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.

Authors:  P A Soons; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 8.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

9.  Nitrendipine kinetics in normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

10.  Effect of allopurinol on caffeine disposition in man.

Authors:  D M Grant; B K Tang; M E Campbell; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

View more
  3 in total

1.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

Review 2.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

3.  Bunazosin in patients with impaired hepatic or renal function.

Authors:  A Halabi; A Nokhodian; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.